ESVS 2024 聚焦更新:紫杉醇涂层器械在无症状 PAD 与间歇性跛行中的应用
本文为 ESVS 对 2024 版无症状外周动脉疾病与间歇性跛行指南的聚焦更新,基于叙述性系统评价重新评估紫杉醇涂层球囊与支架在腹股沟下血运重建中的获益与风险。更新推荐优先监督运动与最佳药物治疗,紫杉醇涂层器械仅限特定再狭窄病例并在充分讨论长期安全性不确定后考虑。
要点
- 监督运动与最佳药物治疗仍为间歇性跛行一线治疗
- 紫杉醇涂层器械临床获益有限且长期全因死亡率可能增加
- 仅对保守治疗无效的特定再狭窄病例可考虑紫杉醇涂层器械
核心结论
- 紫杉醇涂层器械短期手术获益有限,缺乏生活质量改善证据,长期死亡风险仍不确定。
- 间歇性跛行管理应遵循阶梯式策略,优先生活方式干预、运动治疗与最佳二级预防药物。
研究设计与样本
- ESVS 指南写作委员会基于叙述性系统评价,将新随机试验数据纳入更新推荐。
- 更新范围与既往指南一致,针对 Rutherford 0-3 级患者。
主要发现
- SWEDEPAD 2 显示 12 个月 VascuQoL-6 评分差异为 -0.02(95%CI -0.66 至 0.62),无临床相关效果。
- SWEDEPAD 2 报告 12 个月再干预未减少,并提示长期全因死亡率可能增加。
- 其他关键药物涂层球囊试验的长期数据报告无或边际临床获益。
关键数值与推荐
- 仅对保守治疗后仍持续生活方式受限的症状推荐血管内血运重建。
- 紫杉醇涂层器械仅可在充分讨论长期安全性不确定与症状获益有限后,考虑用于特定再狭窄病例。
临床怎么用
- 临床应优先推行监督运动与最佳药物治疗,血运重建保留给依从性好但仍显著受限的患者。
- 使用紫杉醇涂层器械前需与患者共同决策,透明讨论长期死亡风险的不确定性。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This focused update to the European Society for Vascular Surgery (ESVS) clinical practice guidelines (CPGs) on asymptomatic peripheral arterial disease and intermittent claudication (IC) provide revised recommendations on paclitaxel coated devices for endovascular infrainguinal interventions. Recent evidence, particularly from the SWEDEPAD 2 trial, prompted re-evaluation of their efficacy and potential long term risks. As the previously published guidelines were directed towards patients with Rutherford categories 0 - 3, the present update maintains the same scope. METHODS: A narrative systematic review assessed the benefits and risks of paclitaxel coated balloons and stents in infrainguinal revascularisation for IC. The ESVS Guidelines Writing Committee incorporated new randomised trial data into updated recommendations, graded according to the ESVS CPGs recommendation grading system. RESULTS: The updated evidence suggested limited clinical benefit and possible long term harm from paclitaxel coated devices in this population. SWEDEPAD 2 reported no improvement in quality of life (difference in six item Vascular Quality of Life Questionnaire [VascuQoL-6] score at 12 months was -0.02 [95% confidence interval -0.66 - 0.62], indicating no clinically relevant effect) or in reduced re-intervention at 12 months compared with uncoated devices, and indicated a potential excess in the long term all cause mortality rate. These findings corroborate earlier safety concerns raised in a 2018 meta-analysis and in subsequent pooled analyses. Recently published long term efficacy and safety data from some additional pivotal drug coated balloon trials were also considered but reported no or marginal clinical benefits. The update consistently emphasises supervised exercise therapy and best medical therapies as first line treatment. Endovascular revascularisation is recommended only for persistent lifestyle limiting symptoms despite conservative therapy. Paclitaxel coated devices may be considered only for selected cases with re-stenosis following transparent discussion of uncertain long term safety and, at best, modest symptomatic benefit. CONCLUSION: This ESVS focused update integrates emerging evidence to guide contemporary management of IC. Clinicians should carefully balance the limited short term procedural benefits of paclitaxel coated devices against the lack of proven quality of life improvement and the persisting uncertainty regarding long term mortality risk. Management of IC should follow a stepwise approach, prioritising lifestyle modification, exercise therapy, and optimal secondary preventive pharmacotherapy, with revascularisation reserved for compliant patients who remain significantly limited. Emphasis should be placed on conservative management, shared decision making, and continued research to further define the long term safety profile of paclitaxel coated endovascular devices.
引用
- Nordanstig J, Hinchliffe R, Lejay A, et al. Editor's Choice - Focused Update on Paclitaxel Coated Technologies, from the 2024 European Society for Vascular Surgery (ESVS) Guidelines on the Management of Asymptomatic Peripheral Arterial Disease and Intermittent Claudication. Eur J Vasc Endovasc Surg. 2026. PMID: 42248619. doi:10.1016/j.ejvs.2026.04.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。